Clinical Trial Update: GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating GTI-2040 with docetaxel in patients with recurrent/metastatic non-small cell lung cancer or prostate cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• GTI-2040 (GTI-2040)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Non-small Cell Lung Cancer, Recurrent Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED